Lesley Ann Calhoun - 28 Feb 2025 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role: Chief Operating Officer and Chief Financial Officer
Signature: /s/ Lesley Ann Calhoun
Issuer symbol: ALGS
Transactions as of: 28 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2025, 16:32:51 UTC
Previous filing: 06 Sep 2024
Next filing: 09 Jun 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALGS	Stock Option (Right to Buy)	Award	$0	+47,271		$0.000000	47,271	28 Feb 2025	Common Stock	47,271	$16.87	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Operating Officer and Chief Financial Officer